Articles tagged with Cancer Patients
A new study found that RAD51 testing can complement next-generation sequencing in personalizing prostate cancer treatment, especially for patients with homologous recombination repair-defective tumors. The biomarker showed high sensitivity and specificity for identifying BRCA1/2 alterations.
The National Comprehensive Cancer Network is joining the global effort to improve awareness and knowledge of cancer risks through its 'United by Unique' campaign. Patient advocates from NCCN guidelines panels are sharing their personal stories to highlight the importance of a people-centered approach in cancer care, which recognizes ev...
Researchers at the CNIC have designed a treatment strategy to protect the heart against cardiotoxic effects of anthracyclines, a common class of anticancer drugs. Empagliflozin, an SGLT2 inhibitor, has been shown to preserve cardiac function and metabolism in experimental models.
The Neuro-Oncology Translational Research Training Program aims to bridge laboratory discoveries and clinical applications in neuro-oncology, targeting glioblastoma and brain metastases. The program provides predoctoral and postdoctoral trainees with cutting-edge lab experience and mentorship across multiple disciplines.
A new Phase I clinical trial from London Health Sciences Centre Research Institute found high-precision radiation therapy to be safe in treating patients with polymetastatic disease. The study, known as ARREST, used stereotactic ablative radiotherapy (SABR) to treat cancer that has spread to more than 10 spots in the body.
Researchers created a new biologic compound using protein engineering to maximize therapeutic effects while reducing toxicity. The modified enzyme effectively destroyed leukemia cells in mice without common side effects, shrinking tumors in additional cancer models.
A recent study published in Lancet Oncology reveals a significant link between early side effects from radiation therapy for prostate cancer and long-term complications. Men who experience moderate acute urinary or bowel side effects during treatment are nearly twice as likely to develop late urinary or bowel issues, respectively. This...
The addition of da Vinci 5 robotic surgical systems at Huntsman Cancer Institute offers enhanced precision and control during minimally invasive surgeries. The system's advanced technology enables complex procedures to be performed through small incisions, reducing hospital stays and accelerating recovery times for patients.
Researchers at Memorial Sloan Kettering Cancer Center have made a breakthrough in creating allogeneic CAR T cells that can persist in fighting cancer without being rejected by patients. By modifying donor cells with the HIV protein Nef, the cells can survive and remain potent in treating various types of cancer.
A phase 2 clinical trial found that a combination of two HER2 inhibitors was more effective and better tolerated than standard EGFR inhibitor-based therapy for patients with HER2-positive metastatic colorectal cancer. The study showed that the level of HER2 amplification in tumors played a key role in determining treatment outcomes.
Researchers at the University of Pittsburgh have developed a new way to grow T cells that can live longer and better destroy cancer cells in mice. By adding a compound called dichloroacetate to growth media, they created T cells less reliant on glucose and more efficient at using other energy sources.
A pooled data analysis found that cancer chemotherapy is linked to persistent severe peripheral nerve pain for around 4 in every 10 patients, with platinum-based drugs and taxanes associated with the highest rates of painful neuropathy. The study analyzed data from 77 eligible studies involving 10,962 participants from 28 countries.
Researchers tracked cfDNA levels before, during, and after colorectal cancer surgery, revealing significant increases associated with age, comorbidities, and surgical manipulation. The study suggests that cfDNA could serve as a non-invasive biomarker to monitor patient outcomes and evaluate surgical effectiveness.
Research presented at the 2025 STS Annual Meeting reveals that anatomic lung resections such as lobectomy and segmentectomy are associated with improved long-term survival compared to wedge resection for stage 1A NSCLC. Lobectomy offered the highest survival rates, with a 71.9% 5-year OS and 44.8% 10-year OS.
Patients with BRAF V600E mutations showed a 60.9% overall response rate to a combination of encorafenib, cetuximab, and mFOLFOX6 chemotherapy, compared to 40% with standard-of-care treatment. This triple-combination therapy offers an effective new first-line treatment option for patients with this mutation.
A blood test detecting circulating tumor DNA (ctDNA) can predict stage 3 colon cancer patients' risk of recurrence. Adding anti-inflammatory drug celecoxib to post-surgery treatment improves disease-free survival for those with positive ctDNA tests.
The Varian Ethos 2.0 system enables precise and adaptive radiation therapy for multiple types of cancer, including prostate, lung, breast, and others. This technology allows for personalized treatment plans to be updated daily to match the changing anatomy of the patient.
Researchers found that pomalidomide enhances key immune cells, such as T cells and natural killer cells, which helps the body recognize and destroy cancer cells. This leads to improved immune profiles in patients with myeloma, resulting in longer progression-free survival periods.
A University of Minnesota Medical School study reveals that medical equipment is the leading cause of out-of-pocket costs for cancer patients, with wheelchairs and hearing aids among the most expensive items. The research emphasizes the need to address accessibility and affordability issues to improve cancer survivor care.
The RSClin Tool N+ provides more accurate estimates of recurrence risk and individual chemotherapy benefit in node-positive breast cancer. The tool combines clinical and pathologic factors with the 21-gene Oncotype DX Breast Recurrence Score to predict patient-level prognosis and treatment benefit.
University of Oklahoma Health Sciences is part of a new NIH program integrating clinical research into primary care practices in medically underserved areas. The program aims to increase access to vital health care and speed up the adoption of new evidence-based guidelines.
Researchers explore HER2-low breast cancer, a new clinical subtype that benefits from novel treatments and personalized care. Current testing methods are not always accurate, calling for better detection methods to correctly identify patients who can benefit from these new therapies.
Researchers at University of Birmingham have discovered three new protein biomarkers TFF3, LCN2, and CEACAM5 that show strong predictive potential for colorectal cancer. These biomarkers are linked to cell adhesion and inflammation, processes closely associated with cancer development.
Researchers studied the prognostic power of micropapillary patterns in PDAC, finding that even small percentages serve as independent prognostic factors for decreased survival. The study suggests incorporating micropapillary pattern percentage into pathology reports could enhance patient management strategies.
A phase 2 study found that the combination of belzutifan and cabozantinib produced a confirmed objective response rate of 70% among patients with advanced clear-cell renal cell carcinoma. The treatment was well-tolerated, with manageable serious adverse events.
The new NCCN Guidelines for Patients: Genetic Testing for Hereditary Breast, Ovarian, Pancreatic, and Prostate Cancer provide evidence-based recommendations for assessing and testing for inherited genetic mutations. The resource aims to inform individuals about their cancer risks based on personal or family history.
The University Hospitals fundraising campaign, Because of You, has received over $1.5 billion in community support towards its ambitious $2 billion goal. This milestone marks a significant commitment to advancing healthcare services and care for patients across the country.
According to UTHealth Houston research, adolescent and young adult men with cancer have a slightly elevated risk of having preterm birth and children with low birth weight. However, the likelihood of live birth was highest for fathers who had thyroid cancer and lowest for those with gastrointestinal cancer.
The study, published in the Journal of Clinical Oncology, showed no significant difference in patient survival between two-drug and three-drug chemotherapy regimens. The researchers found that the three-drug regimen may increase toxicity but could be a viable option for specific patients with certain types of biliary tract cancers.
The phase 3 KATHERINE clinical trial found trastuzumab emtansine to be an effective adjuvant treatment for high-risk HER2-positive breast cancer patients, reducing the risk of death or invasive disease by 46% and improving survival. The study showed consistent benefits across patient subgroups, supporting T-DM1 as a new standard of care.
A new trial has found that patients with suspected invasive bladder cancer treated with initial MRI imaging and biopsy are faster than those assessed with TURBT alone. The BladderPath trial showed a median time of 53 days from referral to correct treatment, compared to 98 days for usual care.
Researchers developed a system to monitor tumor-informed circulating tumor DNA (ctDNA) after comprehensive genomic profiling (CGP), enabling accurate prediction of patient outcomes. The study showed that this approach can be effectively used in conjunction with CGP data to predict cancer relapse and treatment response, improving person...
A recent population-based study indicates that among children with cancer, those with obesity at the time of diagnosis may face an elevated risk of dying. The study found a significant negative impact of obesity on prognosis, particularly in patients with acute lymphoblastic leukemia and brain tumors.
The book highlights innovative strategies for addressing Latino cancer disparities, including risk assessment, prevention, screening, detection, diagnosis, treatment, survivorship, and policy. It also shares model programs and resources to shape future efforts to address cancer among Latinos and all people.
The National Comprehensive Cancer Network (NCCN) has joined a two-day meeting in Riyadh, Saudi Arabia, to review updated NCCN Clinical Practice Guidelines for the MENA region. The guidelines provide evidence-based expert consensus-driven recommendations for cancer prevention, screening, treatment, and supportive care, tailored for uniq...
A novel patient-derived organoid library of tongue cancer tissue samples reveals new insights into chemoresistance mechanisms, highlighting the importance of autophagy and cholesterol biosynthesis pathways. The research also identifies potential drug targets for overcoming chemotherapy resistance in tongue cancer.
A nationwide cohort study in Korea found that postdiagnosis weight gain is associated with an increased risk of heart failure after breast cancer development. Effective weight intervention can protect cardiovascular health, particularly within the first few years after diagnosis.
Researchers discovered a key role for neutrophils in cancer cell colonization of abdominal fat through the release of DNA webs called NETs. Additionally, a new biomarker study found that dose-dense chemotherapy improved disease-free survival by 20% and overall survival by 15% for women with early-stage ER-positive breast cancer.
A multi-institutional study led by Mayo Clinic researchers has improved the accuracy of genetic testing for BRCA2 variants, enabling precise risk assessments and personalized treatment plans. The findings will aid in identifying patients who may benefit from targeted therapies such as PARP inhibitors.
A recent study found that cancer patients who traveled to local or national healthcare centers had higher five-year survival rates compared to those who remained in their residential cities. The study highlights critical disparities in healthcare resource allocation and quality across regions.
A new study has identified macrophage activity as a key predictor of which skin cancer patients are most likely to respond to immunotherapy. The findings aim to improve personalized medicine for cancer patients and enable clinicians to select effective treatments, reducing side effects and costs.
A large international study of GLP1-RA users and dipeptidyl peptidase-4 inhibitors (DPP-4i) found no evidence that GLP1-RA use is associated with an increased risk of thyroid cancer. The study, published in the Thyroid journal, analyzed data from 92,497 GLP1-RA users and 2,484,408 DPP-4i users.
A University of Cincinnati Cancer Center study identifies microRNA miR-205 as a promising new target to overcome breast cancer treatment resistance and improve outcomes. The research found that boosting levels of miR-205 could block the production of MED1, a protein responsible for treatment resistance, and improve treatment outcomes.
The alliance aims to generate evidence supporting national guideline inclusion and healthcare provider adoption of Myriad's Precise MRD test. The studies will explore the test's utility in breast, gastrointestinal, genitourinary and gynecological cancers.
Weill Cornell Medicine has received a $2.3 million CDC grant to enhance care coordination for young breast cancer survivors, focusing on racially and socio-economically diverse groups to reduce symptom burden and improve survival outcomes.
Researchers analyzed data from over 700 patients with kidney injury and found that glucarpidase treatment improved kidney recovery rates. Glucarpidase rapidly clears methotrexate from the blood, reducing the risk of kidney toxicity.
A new study found that nearly half of high-risk prostate cancer patients have metastatic disease when evaluated with advanced PSMA-PET imaging, suggesting traditional imaging may underestimate cancer spread. This challenge the interpretation of previous studies like EMBARK trial, and support the inclusion of PSMA-PET for patient select...
Two studies suggest that psilocybin-assisted psychotherapy can improve mental health outcomes for patients with cancer and alcohol use disorder, reducing symptoms of anxiety, depression, and obsessive thoughts, while also promoting lasting personality changes.
A new study published in Nature Medicine shows that AI-based models can accurately identify ovarian cancer in ultrasound images, achieving an accuracy rate of 86.3%. The models also reduce the need for expert referrals and misdiagnosis rates by 63% and 18%, respectively.
A new study by Katherine Alexander and Shelley Berger has found a possible source of variability in cancer treatment response in clear cell renal cell carcinoma (ccRCC). The researchers identified two distinct patterns of nuclear speckles in kidney tumors, which may correlate with patient outcomes.
A nationwide cross-sectional study found sepsis incidence and mortality rates among hospitalized non-child cancer patients in China rose significantly, with higher rates observed in older patients.
Researchers have identified three distinct subtypes of osteosarcoma using advanced mathematical modeling and machine learning. This breakthrough could transform clinical trials and patient care by enabling targeted treatment personalized to individual cancer subtypes.
A Phase III clinical trial found that stereotactic body radiotherapy (SBRT) added to sorafenib improved progression-free survival and overall survival in patients with locally advanced hepatocellular carcinoma, particularly those with macrovascular invasion. The study also showed improvements in quality of life for these patients.
A Norwegian study investigates the relationship between volunteers and patients, revealing that intimate disclosures can create an imbalanced dynamic. The researchers emphasize the importance of maintaining professional boundaries to avoid emotional burnout and ensure effective support.
The new therapy significantly improves three-year disease-free survival for children with B-ALL, with 96% being disease-free for at least three years. Blinatumomab is now being used in most patients due to its practice-changing breakthrough, offering improved quality of life and reduced side effects.
Researchers at MD Anderson Cancer Center have made significant breakthroughs in smoking cessation treatments, with a study finding that varenicline plus counseling is the most effective treatment for individuals with major depressive disorder. Additionally, a new radiotherapy technique demonstrates effectiveness in treating metastatic ...
A team of researchers from Wilmot Cancer Institute and University of Rochester Medical Center investigate how social networks influence cancer patients' treatment decisions. They plan to analyze 300 local individuals aged 65+ with advanced cancer, tracking their networks and decision-making processes.
Scientists at the University of Plymouth are creating a humanised meningioma model to study interactions between immune cells and tumour cells, enabling the development of effective therapies for NF2-related schwannomatosis. The model will be made available worldwide to test new treatments and reduce clinical trial delays.
Researchers have developed a new scan that lights up aggressive cancer tumors, allowing doctors to target and treat cancer more effectively. The scan uses a radiotracer to show treatment-resistant tumours on PET scans, giving patients alternative options for better survival rates.
A new study explores whether CBD can reduce scan-related anxiety in advanced breast cancer patients, finding it was safe but did not significantly change anxiety levels. However, participants who consumed CBD experienced lower anxiety levels after treatment.